The Use of PWI and DWI Measures in the Design of "Pro-of-Concept" Stroke Trials

Journal of Neuroimaging

Volumn 14, Issue 2, 2004, Pages 123-132

  Barber, P Alan ^a,c   Parsons, Mark W ^a   Desmond, Patricia M ^a   Bennett, Donald A ^c   Donnan, Geoffrey A ^b   Tress, Brian M ^a,b   Davis, Stephen M ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Ischemic; Magnetic resonance diffusion weighted imaging; Magnetic resonance perfusion weighted imaging; Outcome; Stroke

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL RESEARCH; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; IMAGING SYSTEM; INJECTION; MALE; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PERFUSION WEIGHTED IMAGING; STATISTICAL ANALYSIS; STROKE; WHOLE BODY SCANNER;

ADULT; AGED; AGED, 80 AND OVER; CEREBRAL INFARCTION; CLINICAL TRIALS, PHASE II; DIFFUSION MAGNETIC RESONANCE IMAGING; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROGNOSIS; REGIONAL BLOOD FLOW; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 1642411476     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1177/1051228403259879     Document Type: Article

References (32)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
2. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-2011.
3. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996;276:961-966.
4. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
5. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-1251.
6. Grotta J. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke 1997;28:2338-2346.
7. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998;279:1265-1272.
8. Albers GW, Clark WM, for the ATLANTIS Study Investigators. The ATLANTIS rt-PA (Alteplase) acute stroke trial: final results. Cerebrovasc Dis 1999;9:126.
9. Lees KR, Asplund K, Carolei A, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 2000;355:1949-1954.
10. Davis SM, Lees KR, Albers GW, et al. Selfotel in acute ischemic stroke. Possible neurotoxic effects of and NMDA antagonist. Stroke 2000;31:347-354.
11. Tirilazad International Steering Committee. Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke 2000;31:2257-2265.
12. Sauer D, Allegrini PR, Cosenti A, Pataki A, Amacker H, Fagg GE. Characterization of the cerebroprotective efficacy of the competitive NMDA receptor antagonist CGP40116 in a rat model of focal cerebral ischemia: an in vivo magnetic resonance imaging study. J Cereb Blood Flow Metab 1993; 13:595-602.
13. Madden KP, Clark WM, Zivin JA. Delayed therapy of experimental ischemia with competitive N-methyl-D-aspartate antagonists in rabbits. Stroke 1993;24:1068-1071.
14. De Ryck M, Keersmaekers R, Duytschaever H, et al. Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J Pharmacol Exp Ther 1996;279:748-758.
15. Aronowski J, Strong R, Grotta JC. Treatment of experimental focal ischemia in rats with lubeluzole. Neuropharmacology 1996;35:689-693.
16. Yao H, Ibayashi S, Nakane H, Cai H, Uchimura H, Fujishima M. AMPA receptor antagonist, YM90K, reduces infarct volume in thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats. Brain Res 1997;753:80-85.
17. Warner DS, Martin H, Ludwig P, McAllister A, Keana JF, Weber E. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J Cereb Blood Flow Metab 1995;15:188-196.
18. Zivin JA. Understanding clinical trials. Sci Am 2000;282:69-75.
19. DeGraba TJ, Pettigrew LC. Why do neuroprotective drugs work in animals but not humans? Neurol Clin 2000;18:475-493.
20. Warach S, Pettigrew LC, Dashe JF, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 2000;48:713-722.
21. Parsons MW, Barber PA, Chalk J, et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002;51:28-37.
22. Lövblad KO, Baird AE, Schlaug G, et al. Ischemic lesion volumes in acute stroke by diffusion-weighted magnetic resonance imaging correlate with clinical outcome. Ann Neurol 1997;42:164-170.
23. Barber PA, Darby DG, Desmond PM, et al. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted magnetic resonance imaging. Neurology 1998; 51:418-426.
24. Tong DC, Yenari MA, Albers GW, O'Brien M, Marks MP, Moseley ME. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (< 6.5 hour) ischemic stroke. Neurology 1998;50:864-870.
25. Østergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: a mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-725.
26. Østergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Glydensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: experimental comparison and preliminary results. Magn Reson Med 1996;36:726-736.
27. Parsons MW, Yang Q, Barber PA, et al. Perfusion MRI maps in hyperacute stroke: relative cerebral blood flow most accurately identifies tissue destined to infarct. Stroke 2001; 32:1581-1587.
28. Barber PA, Darby DG, Desmond PM, et al. Identification of major ischemic change: diffusion-weighted imaging versus computed tomography. Stroke 1999;30:2059-2065.
29. Harrell FE. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
30. Barber PA, Davis SM, Infeld B, et al. Spontaneous reperfusion following ischemic stroke is associated with improved outcome. Stroke 1998;29:2522-2528.
31. Baird AE, Benfield A, Schlaug G, et al. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 1997;41:581-589.
32. Ay H, Buonanno FS, Rordorf G, et al. Normal diffusion-weighted MRI during stroke like deficits. Neurology 1999; 52:1784-1792.